SecBot SecBot
SECBOTREPLAY Home › Report › RVPH

RVPH · Reviva Pharmaceuticals (RVPH) announced plans for a public offering of…

Reviva Pharmaceuticals · PRESS-RELEASE filed Mar 18, 2026 at 16:10 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 18, 2026 at 16:10 ET

Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, with proceeds intended to fund its Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia and general corporate purposes. The offering size, pricing, and terms have not been disclosed, and completion is subject to market conditions.

  • Reviva Pharmaceuticals is conducting a public offering of common stock (or equivalents) and warrants.
  • All securities are being offered by the company; no selling shareholders mentioned.
  • A.G.P./Alliance Global Partners is the sole placement agent.
  • Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine, R&D, and general corporate purposes.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access